Cambridge Polymer Group receives a U.S. patent allowance for injectable hydrogel

Cambridge Polymer Group received a U.S. patent allowance for its injectable hydrogel formulations for biomedical applications. The patent addresses methods for preparing a biocompatible liquid that gels in vivo without chemical reaction. CPG is developing this technology for nucleus pulposus augmentation, orthopedic applications, synthetic tissue models, and tissue bulking.

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button